1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Siponimod
Trade Name:
Mayzent
Manufacturer/Distributor:
Novartis Pharmaceuticals Canada Inc.
Classification:
Immunomodulatory agent
ATC Class:
L04AA42 - siponimod
Status:
active
Notice of Compliance (yyyy/mm/dd):
2020/02/02
Date Marketed in Canada (yyyy/mm/dd):
2020/04/24
Presentation:
Tablet: 0.25 mg. DIN: 02496429
Tablet: 2 mg. DIN: 02496437
Comments:
For the treatment of patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features characteristic of multiple sclerosis inflammatory activity, to delay the progression of physical disability.
Back to:
Drug Product Listings 
